SYNTHETIC PEPTIDE AND PEPTIDE CONJUGATES AND RELATED TISSUE COUPLING METHODS VIA TRANSGLUTAMINASE ENZYME
Peptides and conjugates thereof comprising one or more bioactive agents which can be coupled to a tissue via a transglutaminase and related methods.
Latest Northwestern University Patents:
- DEVICES AND METHODS FOR TREATING A STRICTURE ALONG THE BILIARY AND/OR PANCREATIC TRACT
- Systems and methods for the acute evaluation of traumatic brain injuries
- Cancer treatment methods using nanofiber stabilized growth factors
- INSULIN LIKE GROWTH FACTOR BINDING PROTEIN BIOACTIVE PEPTIDE FRAGMENTS
- Dual activity super toxic RNAi active dsRNAs
This application is a divisional of and claims priority benefit from application Ser. No. 12/231,361 filed on Sep. 2, 2008, which claimed priority from application Ser. No. 60/969,081, filed Aug. 30, 2007—each of which is incorporated herein by reference in its entirety.
This invention was made with government support under DE013030 awarded by the National Institutes of Health. The government has certain rights in the invention.
BACKGROUND OF THE INVENTIONStrategies for chemically coupling natural or synthetic molecules to biological surfaces are important tools for drug delivery, tissue repair, and fixation of tissue engineered scaffolds for tissue regeneration. Several methods are capable of attenuating, inhibiting or promoting interactions between tissue surfaces as well as between the cells and extracellular matrix (ECM) proteins that comprise them. Electrostatic interactions have been employed by Elbert et al. in the form of poly-L-lysine-graft-(poly(ethylene glycol) polymers that chemisorb to proteins on tissue surfaces, and this approach was explored as a strategy to minimize postsurgical adhesions. Winblade et al. employed phenylboronic acid modified polymers to provide reversible covalent crosslinks to cis-diols in sugar residues of glycoproteins and polysaccharides. Layer by layer (LbL) assembly of polyelectrolytes has been used to apply polymer coatings onto model biological surfaces, the surface of blood vessels and pancreatic islets.
Specific functional groups found in ECM proteins have been exploited for covalent surface modification strategies. For example, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) and N-hydroxysuccinimide (NHS) have been used extensively to couple macromolecules containing carboxylic acids to protein amines. Amine-reactive PEG diisocyanates have been used to modify pancreatic islets in order to provide immunoprotection, to create a barrier to platelet adhesion on damaged arteries, and on preclotted Dacron and other model biological surfaces. Aldehyde modified chondroitin sulfate, which also reacts with tissue amines, has been used as a tissue adhesive in both the cornea and cartilage. Photochemical oxidation of native tyrosine residues in collagen II has been used to improve the integration of photopolymerized hydrogels with cartilage.
In contrast to chemical or photochemical approaches, a general strategy for tissue surface modification is directed to biological enzyme mediated crosslinking reactions. Transglutaminases (TG) are calcium-dependent enzymes that catalyze crosslinking between lysine and glutamine residues to form ε-(γ-glutaminyl)lysine isopeptide bonds. (See, Lorand L and Graham RM. Transglutaminases: Crosslinking enzymes with pleiotropic functions. Nature Reviews Molecular Cell Biology 2003; 4: 140-156.) There is growing interest in the use of transglutaminase enzymes for tissue repair and reconstruction. Calcium-independent microbial TG has been used to develop gelatin hydrogels for biomedical adhesives as well as for in vitro expansion of cells. Factor XIII, the circulatory form of TG, has been used to form fibrin matrices for in vitro and in vivo studies of neurite growth, angiogenesis, and cartilage regeneration. The incorporation of bioactive peptides and proteins into these matrices was achieved by including a Factor XIII reactive peptide domain within the molecule. Synthetic polymers have also been modified with Factor XIII substrate peptides, which were then crosslinked by the enzyme into a hydrogel. (See, Sanborn T J, Messersmith P B, and Barron A E. In situ crosslinking of a biomimetic peptide-PEG hydrogel via thermally triggered activation of factor XIII. Biomaterials 2002; 23: 2703-2710.)
A transglutaminase enzyme found in many connective tissues and often referred to as tissue transglutaminase (tTG) was used to form hydrogels through crosslinking of glutamine modified poly(ethylene glycol) (PEG) polymers and a lysine containing polyaminoacid. Hu et al. subsequently employed rationally designed peptide substrates of tTG to modify PEG polymers to form an adhesive hydrogel. (See, e.g., Hu B and Messersmith P. Rational design of transglutaminase substrate peptides for rapid enzymatic formation of hydrogels. Journal of the American Chemical Society 2003; 125: 14298-14299; and Hu B and Messersmith P. Enzymatically cross-linked hydrogels and their adhesive strength to biosurfaces. Orthodontic and Craniofacial Research 2005; 8: 145-149.) More recently, tTG has also been used to couple biomolecules to insoluble peptide assemblies, and was used to enhance cell adhesion and spreading on collagen matrices and synthetic polymers coated with fibronectin.
Relating more specifically to a particular disease state, over 70 million people in the US are afflicted with the debilitating pain and inflammation of osteoarthritis (OA), caused primarily by the action of the potent catabolic cytokine interleukin 1 (IL-1). The effects of IL-1 include increased production of matrix metalloproteases and other inflammatory cytokines, inhibition of extracellular matrix (ECM) synthesis, and cell death. Glucocorticoids down regulate the transcription and translation of IL-1, and hence are a major treatment strategy for reducing the pain and inflammation of OA. Locally administered via intra-articular injections to maximize their effects at the inflamed joint and to minimize adverse systemic effects, glucocorticoids are insoluble suspensions which precipitate in the joint space. Nevertheless, a significant portion of the drug dose is still cleared from the joint, entering the circulatory system and exerting unwanted systemic effects including a drop in endogenous cortisol levels, temporary disruption in glucose metabolism, and immunosuppression. In addition, precipitated crystals of glucocortiods may potentially induce inflammation.
Several approaches have been proposed to increase the retention of glucocorticoids in the inflamed joint, mostly relying on introduction of drug-laden vehicles into the intra-articular space. Liposomes of glucocorticoid palmitate esters have been shown to be more effective in reducing knee swelling than the free drug alone. Another method to improve glucocorticoid retention in the joint capsule is modification of hyaluronan (HA) with methyl prednisolone, which method was shown to have better antioxidant properties on chondrocytes than when the two compounds were administered individually. Microspheres and nanospheres have also been utilized as local drug delivery vehicles to joints. However, performance can be problematic and dependent on factors such as the molecular weight and type of polymer used to form the spheres, the extent of crosslinking and particle size. However, such strategies to retain glucocorticoids in the joint space also rely on precipitation of the drug vehicle in the joint, which can lead to problems of the sort encountered with current treatments: potential inflammation and/or elimination via the lymphatic system. As such, there remains in the art an on-going search for an alternate approach for delivery and retention—to realize the benefits associated with such therapeutics.
SUMMARY OF THE INVENTIONIn light of the foregoing, it is an object of the present invention to provide various bioactive and/or therapeutic compounds, compositions and/or methods for their use and delivery, thereby overcoming various deficiencies and shortcomings of the prior art, including those outlined above. It will be understood by those skilled in the art that one or more aspects of this invention can meet certain objectives, while one or more other aspects can meet certain other objectives. Each objective may not apply equally, in all its respects, to every aspect of this invention. As such, the following objects can be viewed in the alternative with respect to any one aspect of this invention.
It can be an object of the present invention to provide an alternate approach to binding a bioactive agent or prodrug thereof to a specific tissue, as can be accomplished using an endogenous or exogenous tissue enzyme.
It can be another object of the present invention to provide for release of such a bound bioactive agent under physiological conditions.
It can be another object of the present invention to enhance efficiencies in administration and delivery of a bioactive agent to a specific tissue target.
It can be another object of the present invention, alone or in conjunction with one or more of the preceding objectives, to provide a molecular platform or architecture for targeted delivery of various and diverse bioactive agents to a wide range of tissue targets.
Other objects, features, benefits and advantages of the present invention will be apparent from the summary and the following descriptions of certain embodiments, and be readily apparent to those skilled in the art having knowledge of various drug delivery systems and related methodologies. Such objects, features, benefits and advantages will be apparent from the above as taken into conjunction with the accompanying examples, data, figures and all reasonable inferences to be drawn therefrom, alone or with consideration of the references incorporated herein.
In part, this invention can be directed to peptide conjugate compounds. Such a compound can comprise a bioactive agent; a peptide component comprising a lysinyl and/or a glutaminyl substrate of a transglutaminase enzyme, and a component coupling such an agent to such a peptide, such a coupling component cleavable under physiological conditions. As would be understood by those skilled in the art made aware of this invention, such a lysinyl substrate can comprise a lysine residue and/or another residue, component and/or moiety capable of amine donor function in the presence of a transglutaminase. Such a glutaminyl substrate can comprise a glutamine residue and/or another residue, component and/or moiety capable of acyl donor function in the presence of a transglutaminase. Likewise, as would be understood by those skilled in the art made aware of this invention, such substrates are limited only by amine or acyl donor function sufficient for or in the context of transglutaminase activity. In certain non-limiting embodiments, such a peptide component can comprise a sequence comprising FKG and/or GQQQLG (SEQ ID NO: 1). Regardless, such a coupling moiety can be hydrolysable, such a moiety including but not limited to an ester.
With regard to the compounds, compositions and and/or methods of this invention, any such lysinyl and/or glutaminyl substrate can be considered in the context of one or more transglutaminase enzymes of the sort discussed herein or as would otherwise be known to those skilled in the art. In certain non-limiting embodiments of this invention, such an enzyme can be selected from tissue transglutaminase enzymes or combinations thereof. In certain other embodiments, such an enzyme can be selected from bacterial transglutaminase enzymes and circulatory transglutaminase (e.g., Factor VIII) enzymes or combinations thereof. Any such enzyme is limited only by function sufficient to couple or cross-link lysinyl and glutaminyl substrates and/or to form ε-(γ-glutaminyl)lysine isopeptide bonds.
Regardless, without limitation as to peptide component or coupling moiety, such a bioactive agent can comprise a prodrug thereof. In certain embodiments, such an agent can be a prodrug of a glucocorticoid. In certain such non-limiting embodiments, such an agent can be a prodrug of hydrocortisone. Without limitation as to the identity of any particular bioactive agent or peptide component, such a compound can be coupled to a tissue substrate comprising one or more ECM components. In certain such embodiments, including those where a bioactive agent comprises a glucocorticoid or a prodrug thereof, such a compound can be coupled to cartilage and/or meniscus tissues.
In part, this invention can also be directed to one or more pharmaceutical compositions. Such a composition can comprise a peptide conjugate compound of the sort discussed above, illustrated elsewhere herein, or would otherwise be understood by one skilled in the art made aware of this invention and/or a pharmaceutically-acceptable salt thereof. Likewise, such compositions can also comprise a pharmaceutically-acceptable carrier. Regardless, in certain such embodiments, such a composition can comprise a transglutaminase to promote compound coupling or binding to a particular tissue substrate.
In part, the present invention can also be directed to a method of tissue modification. Such a method can comprise providing a peptide conjugate compound of this invention; and contacting such a compound and a tissue substrate comprising a lysinyl and/or a glutaminyl substrate, such contact in the presence of a transglutaminase enzyme, such contact and/or enzyme present at least partially sufficient to bind such a compound and tissue substrate. In certain such embodiments, such a substrate can comprise one or more ECM components. Regardless, such a transglutaminase enzyme can be endogenous to such a tissue or introduced in conjunction with such a peptide conjugate. Upon such tissue modification, providing a compound with cleavable and/or hydrolysable coupling component, such an agent can be released from the compound and/or delivered to such a tissue substrate.
Accordingly, the present invention can also be directed to a method of using transglutaminase activity to deliver a therapeutic agent. Such a method can comprise providing a peptide conjugate compound, of the sort described herein, comprising a prodrug component of a therapeutic agent; a peptide component comprising at least one of a lysinyl and a glutaminyl substrate for a transglutaminase, and a component coupling such an agent to such a peptide, such a coupling component hydrolysable under physiological conditions; contacting such a compound and a tissue substrate comprising a lysinyl and/or a glutaminyl substrate, such contact in the presence of a transglutaminase enzyme, such contact and or enzyme presence at least partially sufficient for compound and tissue binding; and hydrolyzing such a compound, to release the therapeutic agent.
Without limitation and as illustrated elsewhere herein, one especially useful embodiment of this invention can be directed to a compound comprising a prodrug of a glucocorticoid, such as but not limited to hydrocortisone. In the presence of a transglutaminase enzyme, whether endogenous or otherwise introduced, such a compound can be coupled to cartilage and/or meniscus tissue. Hydrolysis under physiological conditions can provide for release of a therapeutic agent (e.g., hydrocortisone) for desired therapeutic effect.
As illustrated by several non-limiting embodiments, this invention can be directed to the use of a tTG enzyme as part of a simple and biocompatible approach for coupling one or more therapeutic agents to tissue surfaces. Without limitation, cartilage is a representative tissue for use with this invention, as it is contains tTG as well as several ECM substrates of tTG. In certain embodiments, synthetic peptides comprising, without limitation, lysine and/or glutamine residues and conjugates of such peptides with another molecule, polymer, and/or therapeutic agent can be bound to cartilage surfaces through the action of a tTG enzyme. As discussed below, several cartilage ECM components can be substrates for the reaction. Given the existence of macromolecular tTG substrates in many tissues, this facile approach to tissue modification can be broadly applicable to a variety of tissues for localization of a range of biologically active and/or therapeutic agents and for enhancing (or inhibiting) adhesion at tissue-tissue and tissue-device interfaces.
One non-limiting embodiment, representative of various broader aspects of this invention, can be directed to immobilization of one or more glucocorticoids (and, more broadly, any drug or prodrug) to tissue surfaces for localized therapeutic delivery. Unlike the aforementioned prior art techniques of localized drug delivery, many of which depend on precipitation of the drug delivery vehicle, an approach of this invention covalently attaches the drug to the tissue surface making it resistant to natural fluid turnover in the joint space. In certain embodiments, a peptide substrate, such as but not limited to FKG, can be conjugated to hydrocortisone hemisuccinate, forming a prodrug, TRIP-C (i.e., a transglutaminase immobilized prodrug on cartilage), and can then be coupled to the articular surface of cartilage or to the meniscus. PEGylated or other polymeric variations or forms of such prodrugs (i.e., TRIP-PC) can also be prepared as described herein and used to determine and/or affect tissue binding, prodrug stability and/or delivery.
This invention represents a new and simple approach to direct conjugation of polymers, peptides, proteins, biomolecules and/or a range of therapeutic agents to tissue surfaces. Illustrating several non-limiting embodiments, this invention utilizes a bifunctional molecule and a biological enzyme (e.g., a tTG), as can be pharmaceutically formulated in an aqueous solution or another suitable medium. The bifunctional molecule and enzyme solution is applied to or put in contact with a tissue surface, and the enzyme catalyzes the direct covalent coupling of the bifunctional molecule onto the tissue surface, and/or with proteins contained within the extracellular matrix of the tissue.
tTG is widely distributed within many connective tissues and has been implicated in organogenesis, tissue repair and in tissue stabilization. Cartilage was chosen for purpose of initial demonstration in part because a prior study showed that cartilage tissue surfaces adhered strongly to each other when incubated with tTG enzyme, suggesting a high level of reactivity of cartilage ECM components as substrates for tTG. (Jurgensen K, Aeschlimann D, Cavin V, Genge M, and Hunziker E. A new biological glue for cartilage-cartilage interfaces: tissue transglutaminase. Journal of Bone and Joint Surgery 1997; 79-A: 185-193.) In fact, several components of the cartilage ECM have been identified as substrates for tTG, including osteopontin, collagen II, collagen XI, fibrillin, fibronectin, and osteonectin. See, e.g., Prince C, Dickie D, and Krumdieck C. Osteopontin, a substrate for transglutaminase. Biochemical and Biophysical Research Communication 1991; 177: 1205-1210; Sorensen E, Rasmussen L, Moller L, Jensen P, Hojrup P, and Petersen T. Localization of transglutaminase-reactive glutamine residues in bovine osteopontin. Biochemical Journal 1994; 304: 13-16; Aeschlimann D, Wetterwald A, Fleisch H, and Paulsson M. Expression of tissue transglutaminase in skeletal tissues correlates with events of terminal differentiation of chondrocytes. Journal of Cell Biology 1993; 120: 1461-1470; Aeschlimann D, Kaupp O, and Paulsson M. Transglutaminase-catalyzed matrix crosslinking in differentiating cartilage: identification of osteonectin as a major glutaminyl substrate. Journal of Cell Biology 1995; 129: 881-892; Kleman J P, Aeschlimann D, Paulsson M, and Vanderrest M. Transglutaminase-catalyzed cross-linking of fibrils of collagen V/Xi in A204 rhabdomyosarcoma cells. Biochemistry 1995; 34: 13768-13775; Raghunath M, Cankay R, Kubitscheck U, Fauteck J D, Mayne R, Aeschlimann D, et al. Transglutaminase activity in the eye: Cross-linking in epithelia and connective tissue structures. Investigative Ophthalmology & Visual Science 1999; 40: 2780-2787; Fesus L, Metsis M L, Muszbek L, and Koteliansky V E. Transglutaminase-sensitive glutamine residues of human-plasma fibronectin revealed by studying its proteolytic fragments. European Journal of Biochemistry 1986; 154: 371-37; and Hohenadl C, Mann K, Mayer U, Timpl R, Paulsson M, and Aeschlimann D. Two adjacent N-terminal glutamines of BM-40 (osteonectin, SPARC) act as amine acceptor sites in transglutaminase-catalyzed modification. Journal of Biological Chemistry 1995; 270: 23415-20.
Other known ECM substrates of tTG found in other tissues include collagen I, collagen V, vitronectin, and laminin. (See, Chau D Y S, Collighan R J, Verderio E A M, Addy V L, and Griffin M. The cellular response to transglutaminase-cross-linked collagen. Biomaterials 2005; 26: 6518-6529; Orban J M, Wilson L B, Kofroth J A, El-Kurdi M S, Maul T M, and Vorp D A. Crosslinking of collagen gels by transglutaminase. Journal of Biomedical Materials Research Part A 2004; 68A: 756-762; Kleman J P, Aeschlimann D, Paulsson M, and Vanderrest M. Transglutaminase-catalyzed cross-linking of fibrils of collagen V/Xi in A204 rhabdomyosarcoma cells. Biochemistry 1995; 34: 13768-13775; Sane D C, Moser T L, Parker C J, Seiffert D, Loskutoff D J, and Greenberg C S. Highly sulfated glycosaminoglycans augment the cross-linking of vitronectin by guinea-pig liver transglutaminase-functional-studies of the cross-linked vitronectin multimers. Journal of Biological Chemistry 1990; 265: 3543-3548. Skorstengaard K, Halkier T, Hojrup P, and Mosher D. Sequence location of a putative transglutaminase cross-linking site in human vitronectin. FEBS Letters 1990; 262: 269-274; and Aeschlimann D, Paulsson M, and Mann K. Identification of Gln(726) in nidogen as the amine acceptor in transglutaminase-catalyzed cross linking of laminin-nidogen complexes. Journal of Biological Chemistry 1992; 267: 11316-11321.)
Transglutaminases (TG, protein-glutamine:amine γ-glutamyltransferase, e.g., EC 2.3.2.13) are calcium-dependent enzymes that catalyze a posttranslational acyl-transfer reaction between the γ-carboxamide groups of peptide-bound glutamine residues and the ε-amino groups of lysine residues in proteins, or certain primary amino groups. This reaction results in the formation of ε-(γ-glutamyl)lysine isopeptide side-chain bridges. TG reactions involve two substrates: lysine substrate and glutamine substrate (Scheme 1). The substrate specificity of lysine substrate and glutamine substrate were recently optimized using short peptides by rational design and combinatorial methods. Here, optimized substrate peptides are covalently conjugated to a bioactive and/or therapeutic agent. Solutions of these molecules in the presence of TG enzyme can then be applied to a recipient tissue surface where the TG enzyme catalyzes the covalent attachment of active molecule/agent to the tissue. Accordingly, this invention provides a biocompatible and simple approach to tissue modification, one which can be implemented with any appropriate tissue or on any tissue surface.
A suitable bifunctional molecule can include a peptide containing either a lysine or glutamine amino acid residue or moiety and is preferably a short peptide of six residues or less. The peptide is coupled to a bioactive agent; that is, a molecule which can be a synthetic polymer, a biomolecule (e.g., protein, biologically active peptide, oligosaccharide or polysaccharide, DNA, RNA, antibody, etc.), and/or an agent such as drug, prodrug, or other active component, such as a molecule, agent and/or component that imparts a therapeutic, physiological and/or reparative effect to a tissue. Thus, the approach is modular, includes all combinations of lysinyl/glutaminyl peptide substrates and bioactive agents possible and is limited only by synthetic technique sufficient to couple or conjugate such components.
To demonstrate the general approach of tissue surface modification using tTG enzymes, a simple and versatile molecular module was designed consisting a relatively short synthetic peptide substrate that could ultimately be conjugated to a therapeutic molecule such as a peptide, protein, growth factor, drug or synthetic polymer. Specific requirements for tTG reactive glutamine and lysine residues are not fully understood, although it is believed that the enzyme has more stringent requirements for the glutamine (acyl donor) than for the lysine (amine donor) Recent combinatorial library studies suggest that the amino acid directly adjacent to the reactive glutamine is not as important as the amino acids 2-3 residues away on the C-terminus side. Proline and phenylalanine as well as other nonpolar amino acids have been suggested to have favorable roles in those locations. In contrast, tTG is considered more tolerant of lysine substrates, as it has been found to react with a wide variety of primary amines as well as peptide bound lysines. Nevertheless, certain peptide features do influence lysine reactivity, such as the presence of a C-terminal adjacent glycine or an N-terminal hydrophobic residue juxtaposed to lysine.
The lysine and glutamine-containing peptides used herein were rationally designed, taking such factors into consideration, and shown to be tTG substrates. For instance, both FKG-NH2 and GQQQLG (SEQ ID NO: 1)-NH2 bind to cartilage surfaces via tTG as demonstrated by tissue staining experiments. Various other lysinyl and glutaminyl substrates and sequences useful in the present context would be understood by those skilled in the art made aware of this invention. For instance, numerous glutamine and lysine-containing peptides/sequences (e.g., PQQQYV (SEQ ID NO: 2)) were identified in Hu et at. Method for Screening and MALDI-TOF MS Sequencing of Encoded Combinatorial Libraries. Anal. Chem. 2007, 79, 7275-7285, the entirety of which is incorporated herein by reference. Further, conjugates of these peptides with 3.4 kDa PEG were similarly active, suggesting that the presence of the polymer had little effect on the ability of tTG to catalyze the coupling of the peptide to the tissue surface. (
Peptide conjugates were bound to ECM to a depth of approximately 8-13 microns from the cut tissue surface. The depth of tissue modification can be affected by many factors, including the ability of the enzyme and peptide reactants to diffuse into the tissue before reacting with ECM components. No difference was found for the depth of modification when lysine (B2K) or glutamine (B2Q) peptides were coupled to a 3.4 kDa PEG (B72K and B72Q, respectively), suggesting that the diffusion of the peptide components through the tissue is unlikely to be a limiting factor. The masses of all peptide conjugates are well below that of tTG (77 kDa), suggesting that diffusion of tTG may be a limiting factor. The surface coupling reaction did not require pretreatment of the tissue with chondroitinase, although the depth of tissue modification was greater when the tissue was partially digested. Deeper tissue modification, if desired, may be achieved with a higher concentration of chondroitinase, longer digestion times, or through the use of a different enzyme such as collagenase or hyaluronidase.
To correlate the observed tissue modification to specific matrix components of the tissue, tTG reactions were also conducted in solution using selected cartilage ECM proteins and the peptides. One of the major ECM components of cartilage is collagen II, which can be found throughout the cartilage matrix. Collagen II used in these studies was isolated by pepsin digestion, which yields primarily the triple helical region of collagen II. Both lysine peptide conjugates, B2K and B72K, were reactive toward collagen II, suggesting that glutamine residues in the triple helical region act as substrates for tTG. The B2Q and B72Q containing peptides were less reactive toward collagen II in solution, which could be due to loss of lysine residues as a result of hydroxylation during collagen II interchain crosslinking and glycosylation.
B2K and B72K were significantly (p<0.05) more reactive than B2Q and B72Q with all proteins except osteopontin. There are a few possible explanations for these results. First, FKG has a significantly higher specificity (560 mM−1 min−1) than GQQQLG (SEQ ID NO: 1) (34.1 mM−1 min−1), indicating that the amine donor (FKG) is more reactive with the enzyme than the acyl donor (GQQQLG (SEQ ID NO: 1)). (See, Hu B and Messersmith P. Rational design of transglutaminase substrate peptides for rapid enzymatic formation of hydrogels. Journal of the American Chemical Society 2003; 125: 14298-14299.) However, the reactivities of the glutamine and lysine residues in the ECM proteins may also play important roles and could explain the higher reactivity of osteopontin toward the glutamine peptide conjugates (B2Q and B72Q). In addition, unlike short peptide constructs that are expected to have no secondary or tertiary structure, the existence of alpha helices, beta sheets and higher order protein structures of proteins may shield some lysine and glutamine residues from the enzyme. For example, it has been demonstrated that when fibronectin is exposed to tTG and [14C]putrescine in solution 4 glutamines are reactive. However, after partial digestion, as many as 8-9 glutamines were reactive toward tTG. Thus, the total number of lysine and glutamine residues in an ECM protein may not always be a reliable indicator of potential reactivity toward tTG.
As previously discussed, glucocorticoids provide relief from the pain and inflammation associated with OA by inhibiting IL-1, a potent inflammatory cytokine, and one embodiment of this invention can be used for localized drug delivery to tissues by covalently coupling a hydrocortisone prodrug to tissue surfaces via tissue transglutaminase. By covalently coupling the prodrug to the tissue surface, it is not subject to the joint fluid turnover which could remove drugs nonspecifically bound to the tissue. Accordingly, for reasons outlined above, the lysine substrate peptide was selected to be conjugated to hydrocortisone because the articular surface of cartilage is composed primarily of collagen II, which is readily crosslinked to lysine substrates in the presence of tTG. Considering the low solubility of hydrocortisone, a lysine substrate peptide was expected to enhance solubility of hydrocortisone in aqueous solutions. The molecular design of this particular TRIP-C included a hydrolysable ester linkage or coupling component between hydrocortisone and FKG peptide, allowing the drug to be released from the tissue surface under physiological conditions.
Despite evidence of being hydrolyzed in solution (Table 2, below), TRIP-C was coupled to the articular surface of cartilage via tTG and was detected within 30 μm of the articular surface. The kinetics of TRIP-C immobilization and the dependence on concentration were consistent with an enzyme-mediated reaction. For example, at low TRIP-C concentrations (0.1 and 1.0 mM), the amount of prodrug coupled was concentration dependent. However, at concentrations of 1.0 mM and greater, the amount of prodrug coupled was limited by kcat of the enzyme, as evidenced by a constant amount of bound prodrug despite an increase in concentration. The quantity of prodrug coupled to the articular surface also increased with incubation time and was likely limited by the hydrolytic stability of the prodrug, by the stability of the enzyme, and by competition with hydrolyzed FKG peptide, which remained a substrate of the enzyme. Because the immobilization of the prodrug was enzyme-mediated, it may be possible for more prodrug to be coupled with an increase in enzyme concentration.
The hydrolysis of hydrocortisone from TRIP-C immobilized on the articular surface was examined in Buffer 1, normal bovine synovial fluid, and human osteoarthritic synovial fluid. In both Buffer 1 and normal synovial fluid, the rate of release of hydrocortisone from the cartilage surface into the fluid was less than the rate of solution hydrolysis of the prodrug in the corresponding fluid. This suggests that immobilization of the prodrug onto the tissue via chemical production of an amide bond eliminated the intramolecular catalytic cleavage of the ester, facilitated by the amine group on lysine, and decreased hydrolysis. In addition, the presence of esterases in the synovial fluids were likely responsible for increased prodrug hydrolysis in both solution and on the cartilage surface over that observed in Buffer 1. The lifetime of the prodrug can be increased by altering the sequence and length of the peptide. These changes can potentially influence the ability of esterases to hydrolyze the ester bond. Furthermore, because tTG has a broad substrate specificity for the lysine peptide, a peptide other than FKG may provide more steric inhibition to the intramolecular hydrolysis, while still retaining acceptable levels of reactivity with tTG. While there was an increase in hydrolysis of TRIP-C in the synovial fluids as compared to Buffer 1 due to the presence of esterases, there was no detectable difference between the normal and osteoarthritic synovial fluids. This could be related to the amount of prodrug on the surface, which may have been too small to detect a difference in the rate of hydrolysis between treatments. It is also possible that the esterases from bovine and human sources have different activities. It has been shown that the source of esterases even from different organs within the same animal, may exhibit variable rates of hydrolysis. In order to increase the lifetime of the prodrug on the surface, the addition of hyaluronic acid to the incubating solution could increase the viscosity of the solution and reduce hydrolysis, likely because of decreased enzyme mobility.
Alternatively, consider that PEG has been used previously to camouflage proteins from circulating enzymes and immune cells, and has also been used to make biological surfaces inert to protein deposition and cell adhesion. In addition, it was previously demonstrated that the addition of PEG does not adversely affect enzyme action. Therefore, it was hypothesized that the PEG in TRIP-PC may provide protection for hydrocortisone from hydrolytic enzymes in synovial fluid after coupling to the articular surface. However, at least under the conditions employed, while modification of the prodrug with PEG did not adversely affect its coupling to tissue, there was no difference in hydrocortisone hydrolysis from TRIP-C or TRIP-PC coupled to the articular surface in any of the fluids utilized. This could be due to the length of the PEG, which may not properly cover the articular surface. In addition, the epitopes to which the peptide binds on the articular surface may not be close together and hence coverage of the cartilage is insufficient. The use of a longer PEG, such as 10 kDa to 40 kDa, may provide better coverage and hence reduce hydrolysis.
The articular surface of cartilage is only one joint structure to which the prodrug would be coupled via tTG if injected intra-articularly. TRIP-C in the joint space could in principle be used to modify any tissue bathed in synovial fluid, provided the tissue is composed of tTG substrates such as collagen I, collagen II, collagen XI, fibronectin, vitronectin, and laminin. An example is the meniscus, a fibrocartilage tissue of the knee located between the articulating surfaces of the femur and tibia. As shown in
With respect to the compounds, compositions and/or methods of the present invention, the aforementioned substrates, agents and components can comprise, consist of, or consist essentially of any of the aforementioned sequences, residues, drugs, prodrugs, moieties, components, substituents and functional groups thereof. Each such compound, peptide/sequence/residue, agent, component or moiety/substituent thereof is distinguishable, characteristically contrasted, and can be practiced in conjunction with the present invention separate and apart from another. Accordingly, it should be understood that the inventive compounds, compositions and/or methods, as illustratively disclosed herein, can be practiced or utilized in the absence of any one enzyme compound, agent, peptide, sequence, moiety and/or substituent which may or may not be disclosed, referenced or inferred herein, the absence of which may or may not be specifically disclosed, referenced or inferred herein.
The compounds of this invention may contain an acidic or basic functional group and are, thus, capable of forming pharmaceutically-acceptable salts with pharmaceutically-acceptable acids and bases. The term “pharmaceutically-acceptable salts” refers to the relatively non-toxic, inorganic and organic acid and base addition salts of such compounds. These salts can be prepared by reacting the purified compound with a suitable acid or base. Suitable bases include the hydroxide, carbonate or bicarbonate of a pharmaceutically-acceptable metal cation, ammonia, or a pharmaceutically-acceptable organic primary, secondary or tertiary amine. Representative alkali or alkaline earth salts include the lithium, sodium, potassium, calcium, magnesium, and aluminum salts and the like. Representative organic amines useful for the formation of base addition salts include ethylamine, diethylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine and the like. Representative acid addition salts include the hydrobromide, hydrochloride, sulfate, phosphate, nitrate, acetate, valerate, oleate, palmitate, stearate, laurate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, napthalate, mesylate, glucoheptonate, lactobionate, and laurylsulphonate salts and the like.
A tissue condition or disease state can be treated by contacting a tissue with an effective amount of an inventive compound. The contacting may take place in vitro or in vivo. “Contacting” means that a tissue and such a compound are brought together so that the compound can bind to the tissue. Amounts of a compound effective for tissue treatment may be determined empirically, and making such determinations is within the skill in the art.
To treat an animal/subject, an effective amount of one or more of the present compounds or a pharmaceutically-acceptable salt thereof can be administered. Effective dosage forms, modes of administration and dosage amounts may be determined empirically, and making such determinations is within the skill of the art. It is understood by those skilled in the art that the dosage amount will vary with the activity of the particular compound employed, a particular tissue, tissue condition or disease state, the route of administration, the rate of excretion of the compound, the duration of the treatment, the identity of any other drugs being administered to the animal/subject, the age, size and species of the animal, and like factors well known in the medical and veterinary arts. In general, a suitable daily dose will be that amount which is the lowest dose effective to produce a therapeutic effect. The total daily dosage will be determined by an attending physician or veterinarian within the scope of sound medical judgment. If desired, the effective daily dose of such a compound, or a pharmaceutically-acceptable salt thereof, maybe administered as two, three, four, five, six or more sub-doses, administered separately at appropriate intervals throughout the day. Treatment according to the invention, includes mitigation, as well as elimination, of the tissue or condition or disease state. Animals treatable according to the invention include mammals. Mammals treatable according to the invention include dogs, cats, other domestic animals, and humans.
Compounds of this invention may be administered to an animal/patient for therapy by any suitable route of tissue administration, including articularly or to or by a joint tissue or tissue associated with a joint. While it is possible for the compound(s) (one or more compounds of this invention and/or pharmaceutically-acceptable salts thereof) to be administered alone, it can be preferable to administer the compound(s) as a pharmaceutical formulation (composition). The pharmaceutical compositions of the invention comprise the compound(s) in admixture with one or more pharmaceutically-acceptable carriers and, optionally, with one or more other compounds, drugs or other materials. Each carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. Pharmaceutical formulations of the present invention include those suitable for tissue, articular and/or intrajoint administration. Regardless of the route of administration selected, the compound(s) are formulated into pharmaceutically-acceptable dosage forms by conventional methods known to those of skill in the art.
The amount of the compound(s) which will be combined with a carrier material to produce a single dosage form will vary depending upon the host being treated, the particular mode of administration and all of the other factors described above. The amount of the compound(s) which will be combined with a carrier material to produce a single dosage form will generally be that amount of the compound(s) which is the lowest dose effective to produce a therapeutic effect.
Methods of preparing pharmaceutical formulations or compositions include the step of bringing the active ingredient(s) into association with the carrier and, optionally, one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing the active ingredient(s) into association with liquid carriers, or finely divided solid carriers, or both.
Formulations of the invention suitable for tissue administration may be in the form of a solution or a suspension in an aqueous or nonaqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia) and/or as a gel, each containing a predetermined amount of the compound(s). Liquid dosage forms for tissue administration of the compound(s) include pharmaceutically-acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active ingredient(s), the liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers. Besides inert diluents, the compositions can also include adjuvants such as buffers, esterases, transglutaminases wetting agents, emulsifying and suspending agents.
Examples of suitable aqueous and nonaqueous carriers which may be employed in the pharmaceutical compositions of the invention include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof. Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin or by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
These compositions may also contain adjuvants such as isotonic agents, such as sodium chloride and the like. In addition, effect of an injectable pharmaceutical form may be brought about by the inclusion of agents which promote or delay release or delivery of a bioactive agent.
EXAMPLES OF THE INVENTIONThe following non-limiting examples and data illustrate various aspects and features relating to the compounds, compositions and/or methods of the present invention, including the delivery of various bioactive agents using tissue-targeted peptide conjugates, as are available through the synthetic methodologies described herein. In comparison with the prior art, the present compounds, compositions and/or methods provide results and data which are surprising, unexpected and contrary thereto. While the utility of this invention is illustrated through the use of several bioactive agents and peptide components which can be coupled thereto, it will be understood by those skilled in the art that comparable results are obtainable with various other compounds or compositions, and the bioactive agents and peptide components thereof, as are commensurate with the scope of this invention.
MaterialsRink amide resin was purchased from Anaspec, San Jose, Calif. Fmoc-amino acids were purchased from Peptides International, Louisville, Ky. O—(N-Fmoc-3-aminopropyl)-O′—(N-diglycolyl-3-aminopropyl)-diethyleneglycol (MW 558.6) (Fmoc-NH-(EO)2—COOH) was purchased from Novabiochem, San Diego, Calif. and Fmoc-NH-PEG-NHS (
Applicable to examples 12-23, H-Gly-2-ClTrt-Resin was purchased from Peptides International, Louisville, Ky. All Fmoc-Amino acids, anti-hydrocortisone antibody, and fluorescein conjugated goat anti-mouse secondary antibody were purchased from EMD Biosciences, San Diego, Calif. mPEG amine (
Synthesis of peptide conjugates. The molecules synthesized to demonstrate this invention, for use in this and their abbreviations, are listed in Table 1, above. The peptide portions of the molecules were synthesized on a Rink amide resin (1 g, 0.45 mmol/g) using standard Fmoc solid phase peptide synthesis. Each coupling reaction was performed for 3 hours with a 10 min pre-activation of four equivalents of Fmoc-amino acid: benzotriazole-1-yl-oxy-tris(dimethylamino)-phosphoniumhexafluorophosphate (BOP): N-hydroxybenzotriazole (HOBt): diisopropylethylamine (DIEA) (1:1:1:1) at room temperature. The Fmoc was removed by 20% piperidine in N-methylpyrrolidinone (NMP) for 1 hour. After Fmoc removal from the final amino acid, either Fmoc-NH-(EO)2—COOH or Fmoc-NH-PEG-NHS was added. Fmoc-NH-(EO)2—COOH was treated as Fmoc-amino acid and used at 2 equivalents. The Fmoc-NH-PEG-NHS was used at 2 equivalents and combined with DIEA (1:2) in dichloromethane (DCM), added to the resin and reacted for 2 days. The unreacted peptide on the resin was acetylated with the use of 4 equivalents of acetic anhydride. The Fmoc was then removed and biotin was coupled using 4 equivalents by the previously described procedure for coupling Fmoc-amino acids. At the completion of the reaction, the resin was washed with NMP, DCM, and methanol (MeOH), two times each. The resin was dried under vacuum and then treated with 95% trifluoroacetic acid (TFA), 2.5% water, and 2.5% triisopropylsilane for 3 hours. The crude product was obtained by concentration of the TFA solution and addition of diethyl ether. Purification was performed using semi-preparative RP-HPLC and the masses were confirmed using MALDI-TOF MS analysis on a PE Voyager DE-Pro MALDI-TOF Mass Spectrometer (Perspective Biosystems, MA). The peptide-PEG conjugates were then frozen and lyophilized.
Example 1bCartilage isolation and preparation. For the coupling of peptide conjugates to cartilage sections, osteochondral plugs were extracted from adult bovine metacarpophalangeal joints using a hole punch with a diameter of 0.793 cm. Samples were then frozen in tissue freezing media and stored at −80° C. until use. Vertical sections (25 μm), which included the articular surface as well as a portion of the underlying bone, were cut using a cryostat (Microm HM505N, Carl Zeiss) and the freezing media was removed with 3 washes of Tris buffered saline (TBS) (50 mM Tris, 100 mM NaCl) at pH 7.4. For the penetration studies, four millimeter by two millimeter rectangular samples of cartilage were excised from adult bovine metacarpophalangeal joint to a depth of 200-250 microns from the articular surface. Samples were frozen as described earlier for later use, at which time they were thawed and rinsed in TBS.
Example 2Coupling of peptide conjugates to cartilage sections. A general scheme of the covalent coupling of the peptide-PEG conjugates to cartilage is shown in
Image analysis. Images were analyzed using Metamorph image analysis software (Molecular Devices, Sunnyvale, Calif.). Fluorescein fluorescence was measured at three randomly selected areas of the middle zone on each cartilage section image and then averaged. A similar procedure was utilized to determine Texas Red fluorescence. The fluorescein fluorescence intensity was then normalized to the fluorescence of the Texas Red for each cartilage section image in order to account for potential ECM differences between sections. Finally, the average green fluorescence for each peptide-PEG conjugate was then normalized by dividing by the red fluorescence.
Example 4aDepth of peptide coupling in cartilage. Four millimeter by two millimeter rectangular samples of cartilage were thawed and rinsed, after which the chondroitinase ABC digestion and tTG reactions with the peptide and peptide-PEG conjugates were performed as stated above. (See
Adobe Photoshop (Adobe, Inc, San Jose, Calif.) was used to measure the depth to which the peptide and peptide-PEG conjugates were detected. The depth of staining into the cartilage along the cut surface perpendicular to the articular surface was measured at distances of 60, 120 and 180 microns from the articular surface for each sample. The average depth of staining for each sample was calculated from these three measurements. For each peptide and peptide-PEG conjugate, an overall mean depth of staining was determined from the measurements of three samples.
Example 5Reaction of peptides with cartilage ECM proteins. Fibronectin, collagen II, osteonectin, and osteopontin were separately combined at 0.1% (w/v) in 100 mM Tris and 5 mM CaCl2 with 500 μM peptide-PEG conjugates and 0.05 U/mL tTG. The reaction was allowed to proceed for 30 min at 37° C. and then stopped with the addition of iodoacetamide (1 mM final concentration). Control experiments without transglutaminse were also performed. The proteins were then separated using SDS-PAGE with either 7.5% fibronectin and collagen II) or 10% (osteonectin and osteopontin) gels, transferred to PVDF membranes which were then blocked with 2% BSA in TBS with 0.1% Tween (TBS-T). The modified proteins were probed with peroxidase conjugated ExtrAvidin. Detection of bound ExtrAvidin was accomplished using ECL Plus Western Blotting Detection Reagents and imaged on a Storm 860 imager (GE Healthcare Biosciences, Piscataway, N.J.). Band intensities were measured using ImageQuant (GE Healthcare Biosciences). Statistical analysis was performed using one-way ANOVA and Tukey's post-hoc test with 95% confidence intervals with SPSS (SPSS, Chicago, Ill.). Reactions of B72Q and B72K with osteonectin and osteopontin were dialyzed against 10 mM acetic acid and then analyzed by MALDI-TOF MS.
Example 6aIn the presence of tTG enzyme, B2K, B2Q, B72K, and B72Q were enzymatically crosslinked to the cartilage sections as evidenced by the images of the tissue sections stained with fluorescein anti-biotin antibody (FIGS. A, D, G and H). Fluorescence was detected in all regions of the cartilage, from the articular surface to the calcified zone, although fluorescence intensity was greatest near the lacunae. The B2K and B72K treated samples qualitatively appeared to be more fluorescent than the B2Q and B72Q modified cartilage sections.
Example 6bThe catalytic role of tTG in coupling the peptide-PEG conjugates to cartilage was verified with several controls. First, incubation of B2K and B2Q with the cartilage in the absence of tTG resulted in no observed fluorescence (
Texas Red staining of type II collagen proved to be a useful internal reference for quantifying bound peptide, as red fluorescence was detected in all regions of the cartilage (
In a separate series of experiments, 2 mm by 4 mm by 200-250 μm pieces of cartilage were incubated with each peptide-PEG conjugate and tTG. At the completion of the reaction, the cartilage pieces were frozen and sectioned and the coupled peptide conjugates were detected with a perioxidase anti-biotin antibody. The bound antibody was detected with DAB reagent which forms a brown precipitate in the presence of perioxidase. A representative stained section is shown in
To identify components of the cartilage ECM that were reactive toward the peptide conjugates, enzyme reactions were conducted in solution with fibronectin, collagen II, osteonectin, and osteopontin. Coupling of peptide conjugates to all proteins was observed as evidenced by western blot analysis (
The MALDI-TOF spectrum of osteonectin modified with B72K demonstrated that the majority of the protein was modified with one PEG molecule although additional peaks corresponding to protein modified with up to 4 PEGs were detected (
Fresh articular cartilage was modified with hyaluronan (HA) by exposing to a solution containing Biotin—FKG-HA (modification was 3.8% (using the HABA/Avidin assay). Controls included tissue modification with the bifunctional molecule in the absence of TG, and using peptide (Biotin-Ahx-FKG) without HA and without TG enzyme. The presence of molecule on the tissue surface was detected using an anti-biotin antibody. Only the bifunctional molecule incubated with tissue in the presence of enzyme revealed intense staining. (See,
The same experiment was performed using a peptide functionalized hydrocortisone (HC-GFKG) molecule and visualized using an anti-hydrocortisone antibody. The results shown below indicate the specific coupling of this molecule to the tissue surface. (See,
Synthesis of hydrocortisone prodrugs. Hydrocortisone-GFKG prodrug (TRIP-C) was synthesized on a H-Gly-2-ClTrt resin (1 g, 0.77 mmol/g) using standard Fmoc solid phase peptide synthesis. (See
For synthesis of hydrocortisone-GFKG-PEG, TRIP-PC (
Hydrolysis of the hydrocortisone prodrugs in solution. The hydrolysis of 1.0 mM TRIP-C in Buffer 1 (see Table 1 for buffer compositions) was studied at 4, 23, and 37° C., in Buffer 2 at 4° C., and in Buffer 3 at 37° C. The hydrolysis of 1.0 mM TRIP-PC was evaluated in Buffer 1 at 37° C. A 30 μL portion of each sample was collected at 0.5, 1, 2, 4, 7, 24, and 48 hours and added to a 60 μL mixture of water:acetonitrile:TFA (79:20:1) to prevent further hydrolysis. This solution also contained 2 mM 6α-methyl prednisolone as an internal standard. The samples were then stored at −20° C. until analyzed with RP-HPLC and eluted with a linear gradient of 24-55% acetonitrile in water with 0.1% TFA. The amount of hydrocortisone hydrolyzed from the prodrug was determined by comparing its peak area to that of 6α-methyl prednisolone. The T50% of the prodrug was calculated from 0.693/S, where S is the mean slope giving the best correlation coefficient in the linear part of the logarithmic curve of unhydrolyzed prodrug (1-[hydrocortisone]) versus time. The hydrolysis of 1.0 mM TRIP-C was also studied in 75% normal synovial fluid in Buffer 1 at 37° C. Thirty microliter samples were collected at 10, 20, 30, and 60 minutes and analyzed as previously described.
Example 13Cartilage and meniscus isolation and preparation. Cartilage and meniscus blocks (15 mm×17 mm×5 mm) were cut from the femoral trochea and meniscus, respectively, of 22-week old calves and stored at −80° C. until use. Before use, pieces were thawed in Buffer 1, then rinsed with Buffer 3.
Example 14Coupling of hydrocortisone prodrugs to cartilage and meniscus tissues. A general scheme of the covalent coupling of hydrocortisone prodrugs to cartilage is shown in
The relationship between concentration and coupling was evaluated for TRIP-C at 0.1, 0.5, 1.0, 1.5, and 2.0 mM. The effect of time on the amount of TRIP-C coupled was evaluated at 0.25, 0.5, 1.0, and 2.0 hours using 1.0 mM of the prodrug. In order to study the effect of PEG on coupling, 1.0 mM TRIP-PC was coupled to the articular surface of cartilage in the same manner as TRIP-C. These experiments were conducted and analyzed as previously described.
Example 15Release of hydrocortisone from the coupled prodrugs on the articular surface of cartilage. TRIP-C and TRIP-PC prodrugs were coupled to the articular surface as described above except that all solutions were filter sterilized and manipulation of the cartilage was performed in a sterile laminar flow hood. After the overnight rinse in Buffer 2 with protease inhibitors and the subsequent washes with Buffer 1, each sample was incubated in 100 μL of sterile Buffer 1, normal bovine synovial fluid, or human osteoarthritic synovial fluid at 37° C. At designated time points (4, 12, 24, 48 hours), 10 μL of the fluid were removed from each sample and replaced with 10 μL of fresh fluid. At the end of the experiment, the samples were digested and analyzed as previously described. All samples were tested in triplicate and control experiments were performed with hydrocortisone and TRIP-C in the absence of tTG and evaluated as described above.
Example 16Immunohistochemistry. Modified tissue samples were immersed in tissue freezing media and frozen at −80° C. until use. Tissue slices (25 μm thick) were cut using a cryostat (Microm HM505N, Carl Zeiss) and the freezing media was removed with 3 washes of Buffer 1. Blocking was performed with 4% goat serum in Buffer 1 (blocking buffer) for 1 hour at room temperature. The tissue sections were then incubated with 10 μg/mL mouse anti-hydrocortisone antibody for 1.5 h in the blocking buffer at room temperature, rinsed 3 times with Buffer 1 for 5 minutes each, and then incubated with fluorescein conjugated goat anti-mouse antibody (1/200) in blocking buffer for 1 hour. Samples were rinsed again with Buffer 1 and then imaged using a Leica epifluorescent microscope (λex=495 nm, λem=520 nm for fluorescein) and a SPOT RT digital camera (Diagnostic Instruments, Sterling Heights, Mich.).
Example 17Statistical analysis. Statistical analysis was performed using one-way ANOVA and Tukey's post-hoc test with 95% confidence intervals with SPSS (SPSS, Chicago, Ill.).
Example 18Mass Spectrometry and RP-HPLC analysis of prodrugs. On RP-HPLC, TRIP-C had a retention time of 21.1 minutes (FIG. S2a) and ESI-MS analysis of the product gave an observed mass of 852.78 Da (calculated 851.99). MALDI-TOF analysis of TRIP-PC yielded a mass distribution consistent with the presence of a polydispersed PEG. The mass distribution was centered at 5.8 kDa, demonstrating successful conjugation of the peptide (852 Da) to PEG (5 kDa). On RP-HPLC, TRIP-PC had a retention time of 24.0 min, with an additional peak at 23.0 min, accounting for a 7% impurity in the sample.
Example 19Hydrolysis of hydrocortisone prodrugs in solution. A sample chromatogram of partially hydrolyzed TRIP-C combined with 6α-methyl prednisolone. Using a 24-55% gradient of acetonitrile in water, hydrolyzed hydrocortisone, 6α-methyl prednisolone, and TRIP-C had retention times of 10.1, 14.0, and 16.5 minutes, respectively. A similar chromatogram was observed for TRIP-PC, but with a retention time of 24.0 minutes. Integration of peak area for samples hydrolyzed for different lengths of time allowed for calculation of T50% values, which are listed in Table 2, below. As the incubation temperature decreased, the T50% of hydrolysis of TRIP-PC increased in Buffer 1 from 50.2 min at 37° C. to 57.8 hours at 4° C. A decrease of 3 pH units, from 7.4 to 4.0 at 4° C., also led to an increase in T50% of hydrolysis by a factor of 33. In Buffer 3 at 37° C., the T50% (27 6 min) was lower than in Buffer 1 at the same temperature. Hydrolysis of TRIP-C was 4 times more rapid in synovial fluid than in Buffer 1 at 37° C. Finally, T50% of TRIP-C and of TRIP-PC, 51.1 minutes, were comparable in Buffer 1 at 37° C.
Coupling of TRIP-C to the articular surface. Incubation of TRIP-C with cartilage in the presence of tTG resulted in coupling of the prodrug to the articular surface, as evidenced by the intense immunofluorescence on the tissue surface (
To determine the effect of TRIP-C concentration on the amount of prodrug enzymatically coupled to the articular surface, cartilage blocks were incubated with different concentrations of TRIP-C for 1 hour. With the exception of the lowest concentration (0.1 mM) examined, the samples incubated with tTG had significantly (p<0.05) larger quantities of TRIP-C detected than the respective control samples without tTG (
The time dependency of TRIP-C coupling to cartilage was determined at a prodrug concentration of 1.0 mM. The results revealed a gradual increase in enzyme catalyzed prodrug coupling to the tissue over a period of 120 minutes (
Effect of PEG on prodrug coupling. Addition of a C-terminal PEG to the prodrug did not significantly impact enzymatic coupling to the tissue surface, as both immunohistochemistry and hydrocortisone quantification demonstrated no detectable difference in bound hydrocortisone between TRIP-C and TRIP-PC (
Hydrolysis of hydrocortisone from enzymatically coupled prodrug on the articular surface. The release of hydrocortisone from tissue-bound TRIP-C and TRIP-PC were examined in buffer, bovine synovial fluid and human OA synovial fluid. From 4 to 48 hours of incubation, there was a statistical increase in the amount of hydrocortisone released from the cartilage for samples treated with tTG and TRIP-C, regardless of incubating fluid (p<0.05) (
Immobilization of TRIP-C on meniscus. After incubation of TRIP-C and tTG with meniscus blocks, hydrocortisone was detected on the tissue surface with similar intensity as with cartilage (
Initial results demonstrated that synthetic peptide and peptide-polymer conjugates can be enzymatically coupled to cartilage under mild conditions through the formation of isopeptide bonds between the peptide and ECM proteins. Cartilage is only one example of a tissue with a surface readily accessible through minimally invasive administration of solutions containing tTG and synthetic molecules. Reactive cartilage ECM components can also be found in many other connective tissues, indicating broad applicability of this invention.
More specifically, the preceding data demonstrate transglutaminase immobilization of prodrug molecules onto tissue surfaces as a means of providing localized drug delivery. Hydrocortisone was chemically conjugated to a tTG substrate peptide via a hydrolysable ester linkage and used in conjunction with tTG to immobilize the prodrug onto cartilage and meniscus tissue. Tissue bound drug was then hydrolyzed under physiologic conditions to provide local release of the anti-inflammatory drug. This approach to localizing drugs at a target site is simple and can be conducted at physiologic conditions, creating a “reservoir” of hydrocortisone within the joint space from which it can elute with time. Moreover, this strategy is not limited to the intra-articular space, but can be used to immobilize therapeutic agents on or in other tissue environments.
Claims
1. A method of using transglutaminase activity to deliver a therapeutic agent, said method comprising:
- providing a peptide conjugate compound comprising a prodrug component of a therapeutic agent; a peptide component comprising at least one of a lysinyl and a glutaminyl substrate for a transglutaminase; and a terminal linear monomethoxy poly(ethylene)glycol component coupled to said peptide component; and
- contacting said compound and a tissue substrate comprising at least one of a lysinyl and a glutaminyl substrate for a transglutaminase, said contact in the presence of a transglutaminase enzyme, each of said contact and said enzyme presence at least partially sufficient to bind said compound and said tissue substrate.
2. The method of claim 1 wherein said compound comprises a prodrug of a glucocorticoid.
3. The method of claim 2 wherein said glucocorticoid is hydrocortisone.
4. The method of claim 1 wherein said tissue substrate comprises an extracellular matrix component.
5. The method of claim 4 wherein said compound is bound to one of a cartilage tissue and a meniscus tissue.
6. The method of claim 1 wherein said enzyme is endogenous to said tissue substrate.
7. The method of claim 1 wherein said compound comprises a component coupling said agent to said peptide component, said coupling component hydrolyzable under physiological conditions, said method comprising hydrolyzing said compound to release said therapeutic agent.
8. A method of using transglutaminase activity to deliver a glucocorticoid, said method comprising:
- providing a peptide conjugate compound comprising a prodrug component of a glucocorticoid; a peptide component comprising at least one of a lysinyl and a glutaminyl substrate for a transglutaminase; a component coupling said agent to said peptide, said coupling component hydrolysable under physiological conditions; and a terminal linear monomethoxy poly(ethylene)glycol component coupled to said peptide component;
- contacting said compound and a tissue substrate comprising at least one of a lysinyl and a glutaminyl substrate for a transglutaminase, said contact in the presence of a transglutaminase enzyme, each of said contact and said enzyme presence at least partially sufficient to bind said compound and said tissue substrate; and
- hydrolyzing said compound, to release said glucocorticoid from said compound.
9. The method of claim 8 wherein said glucocorticoid is hydrocortisone.
10. The method of claim 8 wherein said compound is bound to one of a cartilage tissue and a meniscus tissue.
11. The method of claim 8 wherein said enzyme is endogenous to said tissue substrate.
12. A method of using transglutaminase activity to deliver a therapeutic agent, said method comprising:
- providing a peptide conjugate compound comprising a prodrug component of a therapeutic agent; a peptide component comprising a lysinyl substrate for a transglutaminase, said substrate comprising a GFKG sequence; and
- contacting said compound and a tissue substrate comprising a glutaminyl substrate for a transglutaminase, said contact in the presence of a transglutaminase enzyme, each of said contact and said enzyme presence at least partially sufficient to bind said compound and said tissue substrate.
13. The method of claim 12 wherein said compound comprises a prodrug of a glucocorticoid.
14. The method of claim 13 wherein said glucocorticoid is hydrocortisone.
15. The method of claim 12 wherein said tissue substrate comprises an extracellular matrix component.
16. The method of claim 15 wherein said compound is bound to one of a cartilage tissue and a meniscus tissue.
17. The method of claim 12 wherein said enzyme is endogenous to said tissue substrate.
18. A method of using transglutaminase activity to deliver a glucocorticoid, said method comprising:
- providing a peptide conjugate compound comprising a prodrug component of a glucocorticoid; a peptide component comprising a lysinyl substrate for a transglutaminase, said substrate comprising a GFKG sequence; and
- contacting said compound and a tissue substrate comprising a glutaminyl substrate for a transglutaminase, said contact in the presence of a transglutaminase enzyme, each of said contact and said enzyme presence at least partially sufficient to bind said compound and said tissue substrate.
19. The method of claim 18 wherein said glucocorticoid is hydrocortisone.
20. The method of claim 19 wherein said compound is bound to one of a cartilage tissue and a meniscus tissue, said enzyme endogenous to said tissue substrate.
Type: Application
Filed: Mar 12, 2013
Publication Date: Sep 26, 2013
Applicant: Northwestern University (Evanston, IL)
Inventors: Phillip B. Messersmith (Clarendon Hills, IL), Marsha Ritter-Jones (Chicago, IL)
Application Number: 13/797,492
International Classification: C07K 17/00 (20060101);
